
|Videos|September 30, 2022
Clinical Implications of the CHECKMATE 9ER Trial
Author(s)Daniel J. George, MD
Dr Daniel J George reviews long term follow up data from the CHECKMATE 9ER and the implications of the data in the treatment paradigm for patients with advanced renal cell carcinoma.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5










































